Serum alpha-1 antitrypsin in acute ischemic stroke: A prospective pilot study

Area of Science:

• Neuroscience
• Cardiovascular Medicine
• Biochemistry

Background:

• Alpha-1 antitrypsin (AAT) is an anti-protease enzyme potentially involved in arterial wall stability.
• A genetic variant of AAT has been associated with large artery atherosclerosis (LAA) ischemic stroke.
• The relationship between stroke mechanisms, atherosclerosis, and serum AAT levels requires further investigation.

Purpose of the Study:

• To explore the association between serum AAT levels and atherosclerosis burden in acute ischemic stroke patients.
• To investigate potential links between AAT levels and different ischemic stroke mechanisms.

Main Methods:

• Prospective observational study of 18 acute ischemic stroke patients.
• Serum AAT levels measured within 24 hours of admission.
• Atherosclerosis burden quantified using the modified Woodcock calcification scoring system.
• Linear regression analysis to assess associations between AAT levels and calcification scores.

Main Results:

• Higher serum AAT levels were significantly associated with lower modified Woodcock calcification scores (p=0.038).
• No significant difference in median AAT levels was observed between LAA-related stroke and other stroke mechanisms (p=0.26).

Conclusions:

• Measuring serum AAT levels in acute stroke patients is feasible.
• Preliminary findings suggest a potential association between AAT levels and stroke mechanisms, particularly regarding atherosclerosis.
• Further research with larger sample sizes is warranted to confirm these associations.